Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.50 |
| ▸ | GRM5 | P41594 | 9/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30023252 | 0.89 | GRM1 (0.48) | GRM1GRM5PDK4TNK2CYP11B2 | |
| SCHEMBL17837379 | 0.89 | GRM1 (0.48) | GRM1GRM5PDK4TNK2CYP11B2 | |
| SCHEMBL17838317 | 0.86 | GRM1 (0.51) | GRM1GRM5PDK4TNK2CYP11B2 | |
| SCHEMBL17857746 | 0.85 | GRM1 (0.46) | GRM1GRM5PDK4TNK2CYP11B2 | |
| SCHEMBL17837639 | 0.84 | GRM1 (0.57) | GRM1GRM5PDK4TNK2JAK1 | |
| SCHEMBL17844393 | 0.83 | ALDH1A1 (0.36) | GRM1GRM5 | |
| SCHEMBL24597336 | 0.79 | GRM1 (0.51) | GRM1GRM5PDK4TNK2CYP11B2 | |
| SCHEMBL30567529 | 0.79 | GRM1 (0.51) | GRM1GRM5PDK4TNK2CYP11B2 | |
| SCHEMBL22290520 | 0.77 | GRM1 (0.53) | GRM1GRM5PDK4TNK2NAMPT | |
| SCHEMBL18755022 | 0.77 | PDK4 (0.53) | GRM1GRM5PDK4TNK2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176850-A1 | AXL INHIBITORS | AXL, FLT3, MERTK | GRM1 1082/4885GRM5 1645/4885PDK4 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.